(R)-2-bromo-1-(4-(trifluoromethoxy)phenyl)ethanol | 1492020-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (R)-2-bromo-1-(4-(trifluoromethoxy)phenyl)ethanol
• 英文别名: (1R)-2-bromo-1-[4-(trifluoromethoxy)phenyl]ethanol
• CAS: 1492020-34-4
• 化学式: C₉H₈BrF₃O₂
• 分子量: 285.061
• InChiKey: ZUJNWFLSKRUUFX-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-溴-1-4-(三氟甲氧基)苯基乙酮 在 Almag CRED A₁₃₁ 、 NADP 、 glucose dehydrogenase 作用下， 以 水 、 二甲基亚砜 、 异丙醇 为溶剂， 35.0 ℃ 、50.0 kPa 条件下， 以54%的产率得到(R)-2-bromo-1-(4-(trifluoromethoxy)phenyl)ethanol
  参考文献：
  名称：

  Preparative access to medicinal chemistry related chiral alcohols using carbonyl reductase technology

  摘要：

  Libraries of highly enantioenriched secondary alcohols in both enantiomeric forms were synthesised by enzymatic reduction of their parent ketones using selectAZyme (TM) carbonyl reductase (CRED) technology. Commercially available CREDs were able to reduce a range of substrate classes efficiently and with very high enantioselectivity. Matching substrate classes to small subsets of CREDs enabled the fast development of preparative bioreductions and the rapid generation of 100-1500 mg samples of chiral alcohols in typically >95% ee and the majority in >= 99.0% ee. The conditions for small scale synthesis were then scaled up to 0.5 kg to deliver one of the chiral alcohols, (S)-1-(4-bromophenyl)-2-chloroethanol, in 99.8% ee and 91% isolated yield. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2013.09.015

文献信息

• SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：US20150031685A1

  公开（公告）日：2015-01-29

  The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

  本发明涉及一系列具有一般式（I）的取代化合物，包括其立体异构体和/或其药学上可接受的盐，其中R1、R2、R3、R4、R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括中间体。本发明的化合物在kappa (κ) 阿片受体 (KOR) 位点上具有有效性。因此，本发明的化合物在制药剂中是有用的，特别是在治疗和/或预防各种中枢神经系统疾病 (CNS) 中，包括但不限于急性和慢性疼痛及相关疾病，尤其在中枢神经系统周边的功能方面。
• Preparative access to medicinal chemistry related chiral alcohols using carbonyl reductase technology
  作者：Andrew S. Rowan、Thomas S. Moody、Roger M. Howard、Toby J. Underwood、Iain R. Miskelly、Yanan He、Bo Wang

  DOI：10.1016/j.tetasy.2013.09.015

  日期：2013.11

  Libraries of highly enantioenriched secondary alcohols in both enantiomeric forms were synthesised by enzymatic reduction of their parent ketones using selectAZyme (TM) carbonyl reductase (CRED) technology. Commercially available CREDs were able to reduce a range of substrate classes efficiently and with very high enantioselectivity. Matching substrate classes to small subsets of CREDs enabled the fast development of preparative bioreductions and the rapid generation of 100-1500 mg samples of chiral alcohols in typically >95% ee and the majority in >= 99.0% ee. The conditions for small scale synthesis were then scaled up to 0.5 kg to deliver one of the chiral alcohols, (S)-1-(4-bromophenyl)-2-chloroethanol, in 99.8% ee and 91% isolated yield. (C) 2013 Elsevier Ltd. All rights reserved.